RespiQ
Smart breath testing for personalized health management.
RespiQ is a Dutch based start-up developing a breakthrough smart breath testing system to predict and potentially prevent COPD lung attacks @home, preventing hospitalizations and healthcare costs and radically improve COPD patients everyday life. RespiQ’s smart handheld breathalyzer will offer a non-invasive and affordable health monitoring solution that enables COPD patients to easily monitor their health daily at home. Smart predictive algorithms analyze the breath and provide instant health insights. Clinicians can remotely review patients’ data which will allow for earlier intervention with the aim to prevent lung attacks, and hospitalization. Our mission is to improve the health of millions of people! We won’t stop at COPD, beyond COPD there are several opportunities where our tech can play an important role, like asthma and cancer.
Significant progress in Product Development in the last 18 months: device size reduced by 10x, device sensitivity increased by 100x, produced the first silicon wafer for breath testing on a chip.
Preparing for 2 clinical trials starting in 2025 in the areas of Food Intolerance and COPD
Successfully led the application as consortium lead for 2 key European grants totaling €5.2m of which €2.1m for RespiQ in addition to approx. €1m in other non-dilutive funding: EIC Pathfinder (€4m of which €1.8m for RespiQ (2023)), Eurostars (€1.2m of which €300k for RespiQ (2022)), other non-dilutive funding for approx. €1m, BioTechBooster €160k (final confirmation pending).
